Skip to main content
Premium Trial:

Request an Annual Quote

Strand Life Sciences StrandAdvantage Genomic Profiling Service

Strand Genomics said this week that it will introduce its expanded StrandAdvantage pan-cancer genomic profiling service at the American Society of Clinical Oncology meeting in Chicago next week. The new version of StrandAdvantage will include a panel that examines 152 genes and pathways known to be impacted by existing targeted cancer therapies plus additional chemotherapeutic toxicity and resistance data. The service provides oncologists with clinically actionable results beginning with a report on eight "standard-of-care" genes delivered to the oncologist within eight days. A full report is provided within 15 days that covers all major gene variants and pathways known to be impacted by existing targeted therapies.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.